Immunogenicity of a novel inactivated canine adenovirus type 2 variant vaccine for dogs.

IF 2.1 Q4 IMMUNOLOGY Clinical and Experimental Vaccine Research Pub Date : 2024-07-01 Epub Date: 2024-07-31 DOI:10.7774/cevr.2024.13.3.253
Dong-Kun Yang, Sangjin Ahn, Hye Jeong Lee, Minuk Kim, Jong-Taek Kim, Ju-Yeon Lee, Yun Sang Cho
{"title":"Immunogenicity of a novel inactivated canine adenovirus type 2 variant vaccine for dogs.","authors":"Dong-Kun Yang, Sangjin Ahn, Hye Jeong Lee, Minuk Kim, Jong-Taek Kim, Ju-Yeon Lee, Yun Sang Cho","doi":"10.7774/cevr.2024.13.3.253","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The immunogenicity of vaccines containing the canine adenovirus (CAdV) type 2 (CAdV-2) variant has not yet been reported. We prepared a novel inactivated CAdV-2 variant vaccine using the CAV2232-41 strain, and evaluated its safety and immunogenicity in raccoon dogs.</p><p><strong>Materials and methods: </strong>The growth kinetics of CAV2232-41 were determined using Madin-Darby Canine Kidney (MDCK) cells. The nucleotide sequences of CAV2232 and CAV2232-41 were determined by next-generation sequencing. To generate the CAdV-2 variant vaccine, CAV2232-41 propagated in the MDCK cells was inactivated with 0.1% formaldehyde. Two vaccines were prepared by blending inactivated CAV2232-41 with Cabopol and Rehydragel adjuvants. Safety and immunogenicity of the CAV2232C and CAV2232R vaccines were evaluated in guinea pigs. Safety and immunogenicity of the CAV2232C vaccine were also evaluated in raccoon dogs. The virus neutralizing antibody (VNA) titer against CAV2232-41 was measured in sera collected from immunized guinea pigs and raccoon dogs.</p><p><strong>Results: </strong>CAV2232-41 showed the highest viral titer on days 4-6 post-inoculation and had a deletion in the E3 gene, which was confirmed as a CAdV-2 variant. Guinea pigs inoculated with CAV2232C showed slightly higher VNA titers than those inoculated with CAV2232R 2 weeks after booster vaccination. Raccoon dogs immunized with the CAV2232C vaccine developed high mean VNA titers, while non-vaccinated raccoon dogs were antibody-negative.</p><p><strong>Conclusion: </strong>The CAV2232C vaccine is safe and induces a protective VNA titer in raccoon dogs.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 3","pages":"253-258"},"PeriodicalIF":2.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319112/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2024.13.3.253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The immunogenicity of vaccines containing the canine adenovirus (CAdV) type 2 (CAdV-2) variant has not yet been reported. We prepared a novel inactivated CAdV-2 variant vaccine using the CAV2232-41 strain, and evaluated its safety and immunogenicity in raccoon dogs.

Materials and methods: The growth kinetics of CAV2232-41 were determined using Madin-Darby Canine Kidney (MDCK) cells. The nucleotide sequences of CAV2232 and CAV2232-41 were determined by next-generation sequencing. To generate the CAdV-2 variant vaccine, CAV2232-41 propagated in the MDCK cells was inactivated with 0.1% formaldehyde. Two vaccines were prepared by blending inactivated CAV2232-41 with Cabopol and Rehydragel adjuvants. Safety and immunogenicity of the CAV2232C and CAV2232R vaccines were evaluated in guinea pigs. Safety and immunogenicity of the CAV2232C vaccine were also evaluated in raccoon dogs. The virus neutralizing antibody (VNA) titer against CAV2232-41 was measured in sera collected from immunized guinea pigs and raccoon dogs.

Results: CAV2232-41 showed the highest viral titer on days 4-6 post-inoculation and had a deletion in the E3 gene, which was confirmed as a CAdV-2 variant. Guinea pigs inoculated with CAV2232C showed slightly higher VNA titers than those inoculated with CAV2232R 2 weeks after booster vaccination. Raccoon dogs immunized with the CAV2232C vaccine developed high mean VNA titers, while non-vaccinated raccoon dogs were antibody-negative.

Conclusion: The CAV2232C vaccine is safe and induces a protective VNA titer in raccoon dogs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型犬腺病毒 2 型变异灭活疫苗的免疫原性。
目的:含有犬腺病毒(CAdV)2型(CAdV-2)变异株的疫苗的免疫原性尚未见报道。我们使用 CAV2232-41 株制备了一种新型 CAdV-2 变体灭活疫苗,并评估了其在浣熊犬中的安全性和免疫原性:使用Madin-Darby犬肾(MDCK)细胞测定了CAV2232-41的生长动力学。通过新一代测序确定了 CAV2232 和 CAV2232-41 的核苷酸序列。为了产生CAdV-2变体疫苗,在MDCK细胞中繁殖的CAV2232-41用0.1%甲醛灭活。将灭活的CAV2232-41与Cabopol和Rehydragel佐剂混合,制备出两种疫苗。在豚鼠身上评估了 CAV2232C 和 CAV2232R 疫苗的安全性和免疫原性。还在浣熊犬身上评估了 CAV2232C 疫苗的安全性和免疫原性。从免疫豚鼠和浣熊犬采集的血清中测定了针对 CAV2232-41 的病毒中和抗体 (VNA) 滴度:结果:CAV2232-41在接种后第4-6天的病毒滴度最高,其E3基因有缺失,被确认为CAdV-2变种。接种 CAV2232C 的豚鼠在加强免疫 2 周后的 VNA 滴度略高于接种 CAV2232R 的豚鼠。接种 CAV2232C 疫苗的浣熊犬平均 VNA 滴度较高,而未接种疫苗的浣熊犬抗体阴性:结论:CAV2232C 疫苗是安全的,可诱导浣熊犬产生保护性 VNA 滴度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.70
自引率
3.70%
发文量
29
审稿时长
8 weeks
期刊介绍: Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
期刊最新文献
Completing the pieces of a puzzle: in-depth probing of Toxoplasma gondii rhoptry protein 4 as a promising target for vaccination using an in-silico approach. COVID-19 vaccine hesitancy among medical students, health professionals, and health care workers: an umbrella review. Anti-severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain antibody levels in patients with systemic lupus erythematosus based on vaccination status and related factors in Indonesia. Effect of SpikoGen subunit vaccine administration during pregnancy on fetal development of rats. Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1